



**Nederlandse  
Zorgautoriteit**

# **Healthcare Liberalisation in The Netherlands: The role of the Dutch Healthcare Authority (NZa)**

**Ms Cathy van Beek, Msc MCM  
Acting chair of NZa**

**Commonwealth Fund and Alliance for Health  
Reform Briefing November 6, 2009**

# Overview

- **Reform and public policy objectives**
- **Cost of healthcare in The Netherlands**
- **Market failures in healthcare**
- **The idea behind competitive healthcare markets**
- **The role of the NZa**
- **Conclusion: 2 pieces of friendly advice**


# Seven key characteristics of the Dutch system

- **Market driven**
  - 100% private health insurers
  - 100% private healthcare providers
- **Consumer oriented**
  - General consumer interest leading objective
- **Within regulatory framework**
  - Full coverage of the population
  - Increasing “step by step” liberalisation of prices
  - Independent regulator/sector-specific competition authority
  - Comprehensive system of largely ex ante risk adjustment

# Reform and public policy objectives


- **Cutler (2002): successive waves of healthcare reform aiming at**
  - Ensuring universal access to healthcare
  - Centralised regulation-based cost containment by various rationing mechanisms
  - Decentralised market- and incentive-based systems
- **Promoting effective competition is not a goal in itself but is seen as the best way to deliver the key public policy objectives of:**
  - **Accessibility**
  - **Affordability**
  - **Quality**
- **These three dimensions of the general consumer interest are the NZa's key objectives**

## Healthcare and life expectancy in the Netherlands



Source:  
CBS


# Market failures in healthcare



# Characteristics of the Dutch health insurance market

- **2005/2006 healthcare reform. Legal framework provides for:**
  - **Mandatory health insurance for all Dutch citizens + tax subsidy for lowest incomes**
  - **Obligation for all health insurers to provide services to all consumers without:**
    - **risk selection**
    - **premium differentiation**
  - **Funding regime:**
    - **50% of the premium is a nominal premium (differentiated per insurer not per consumer) and collected by insurers**
    - **50% of the premium is income dependent and collected by the state (this part of the premium is redistributed to insurers based on a risk adjustment system)**
  - **Risk adjustment system: to avoid adverse selection and moral hazard and promote competition on the merits**

# The idea behind competitive healthcare markets





# Economic characteristics of healthcare competition

- **Consumers have free choice of health insurance company, no risk selection, no lock-in**
- **Competition between health insurance companies leads to downward pressure on costs:**
  - **Selective contracting with healthcare providers**
  - **Directing consumers toward more efficient choices**
- **Utilization review by insurers:**
  - **Crosschecking need for treatment received**
  - **Best practice benchmarking**
- **So far these developments are in their infancy**

# The Dutch regulatory landscape for healthcare

- **The CVZ (Health Insurance Authority)**
  - Advice on scope of basic insurance
  - Administration of risk adjustment system
- **The IGZ (Healthcare Inspection Agency)**
  - standard setting and enforcement role in quality control
- **The NMa (Netherlands Competition Authority)**
  - *ex post* regulation of dominant market positions
  - decisive role in merger control
  - enforcing cartel prohibitions
- + **General regulators for behavioural and solvency aspects of financial supervision (Central Bank DNB and Securities Authority AFM)**

# Role of NZa as independent regulator

1. **Market supervision/market development relating to 3 market types**
  - healthcare insurance market
  - healthcare provision market
  - healthcare contracting market
2. **Tariff and performance regulation**
  - setting prices and budgets
  - defining standard product categories
3. **Supervision of the lawful execution of the Health Insurance Act**
  - the duty of care
  - open enrolment
  - community rating
4. **Supervising lawful & effective execution of Act on Long Term Care**
5. **Advising the Health Minister both on request and ex officio (advocacy)**

# Role NZa as sector-specific competition authority

- **Key elements of supervision: public interest**
  - Accessibility, affordability, quality
- **Specific powers to promote effective competition**
  1. **Significant Market Power (SMP) in markets with dominant players**
    - Impose proportionate obligations (from transparency to price controls)
  2. **Intervene in conditions of agreements and manner in which they are concluded**
    - In the event of structural problems
    - e.g. mandate access or strike out exclusivity or impose auction requirement
- **Close cooperation with general competition authority**
  - Concurrent powers relating to market power and (anticompetitive) agreements
  - NZa advises on merger control
  - Joint development of instruments e.g. methods of market definition/merger simulation
- **Powers to grant state aid in process of development towards principles of least intervention and consistency**

## Conclusion: two points of advice in the context of US reforms

1. The need for a(n independent) sectoral regulator with competition powers
2. The even greater need for a comprehensive system of risk adjustment as *sine qua non* for both
  - Competitive private insurance markets with full coverage
  - Competitive markets including a public option

Thank you for your attention!

**cbeek@nza.nl**

Questions?

Nederlandse Zorgautoriteit



# Risk adjustment system

- **Remove financial incentives for risk selection**
  - Compensates insurers for predictable losses
  - Insurers will make an effort to efficiency instead of risk selection
  - Fair competition among insurers
- **Ex-ante risk adjustment**
  - Age, sex, source of income (e.g. salary, subsidy)
  - Region (classification of postcode areas based on socio-economic, demographic and healthcare related characteristics of the postcode area)
  - Recent outpatient drug consumption (chronic diseases)
  - Diagnose (was the patient treated in hospital last year, and does this predict further high cost treatments/ drugs?)
- **Ex-post risk adjustment**
  - Correction of the ex-ante adjustment. Necessary e.g. because of the changes in case mix from one year to the next, general cost increase, unexpected high costs
  - Net yearly risk per enrolled consumer 35 Euro